SharePoint
A- A A+

Measles

Measles

Causative Agent

Measles (Rubeola) virus

Incubation Period

8 - 14 days.

Infectious Period

Just before onset of prodromal symptoms to within 4 days after onset of the rash (usually 4 days before to 4 days after rash onset).

Transmission

Airborne transmission by respiratory droplets and by direct contact with nasal or throat secretions and less commonly by articles freshly soiled with nose and throat secretions.

Epidemiology

Measles vaccination was first introduced into the childhood vaccination programme in October 1976 and made compulsory in August 1985. The monovalent measles vaccine was replaced by the trivalent measles, mumps, rubella (MMR) vaccine in January 1990. The vaccination coverage was between 85% and 89% and the annual incidence of the disease declined to between 123 and 218 cases during the period 1985-1991. A resurgence of measles was noted in 1992 - 1993 but the highest incidence was seen in 1997 when a total of 1413 cases were notified. This resurgence was not due to vaccine failure but a build-up of susceptibles among older children, youths and adults who were not vaccinated. A catch-up measles (MMR) vaccination campaign was conducted in July-November 1997 for all students aged 12-18 years. In January 1998, the two-dose MMR vaccination schedule was introduced with the second dose given to primary school leavers (11+ years old).

There were 13 laboratory confirmed cases of measles reported in 2009, including 5 foreigners who sought medical treatment in Singapore.


  • Seldom seen in infants less than five months of age (due to passively transferred protective maternal antibodies).
  • High fever and toxic looking.
  • Cough, Coryza and Conjunctivitis (the 3 C’s).
  • Koplik’s spots appear during the febrile phase. These are 1 - 2 mm diameter whitish-grey spots surrounded by erythematous rings at the buccal mucosa opposite the molar teeth.
  • The rash appears on the fourth or fifth day - first behind the ears, or over the eyelids, then spreading to the rest of the face and upper neck and then the rest of the body (centrifugal, top down).
  • When the rash appears, the fever becomes higher and the child appears more ill. The fever lasts for another 3 - 4 days. The Koplik’s spots disappear by the second day of appearance of the rash.
  • The rash fades after about five days but there is staining of the skin for days to weeks.
  • Differential diagnoses of the rash can include :
    • Roseola infantum
    • Rubella
    • Other viral exanthem (ECHO, coxsackievirus, parvovirus B19, etc)
    • Kawasaki disease
    • Drug rash.


  • Laboratory confirmation of measles MUST be attempted for all cases, preferably by serologic tests. A fourfold or greater increase in measles antibody titre in acute and convalescent serum specimens is diagnostic of measles.
  • Immunofluorescence (IF) of cells from nasal exudates is useful for a rapid diagnosis (false positive results have been reported).
  • Detection of specific IgM antibody is useful for the diagnosis of acute measles on one serum sample.
  • Measles PCR available on research basis. This is rapid, diagnostic, specific (and sensitive if done within the 1st 4 days of rash onset) but costly.
  • A chest X-ray should be done if respiratory symptoms and signs indicate pneumonitis, or a secondary bacterial pneumonia.


A legally notifiable disease in Singapore. Notify Ministry of Health (Form MD 131 or electronically via CD-LENS) not later than 72 hours from the time of diagnosis.



  • Symptomatic measures: anti-pyretics, tepid sponging, cough suppressants and anti-histamines.
  • Hospitalisation for treatment of complications.
  • Oxygen should be provided for all individuals with measles who develop respiratory distress.
  • Antibiotics (especially against Staphylococcus) are used when there is evidence of secondary bacterial infection e.g. raised total white counts.
  • Intravenous immunoglobulin (polyclonal or measles-specific) and intravenous and/ or nebulised ribavirin have been used with success in some immunocompromised patients.
  • Two doses of 200,000 IU (megadose) vitamin A given over 2 days to children with measles (especially hospitalised children) in areas with high case-fatality rates can reduce measles-related overall and pneumonia-specific mortality by 64-83%. This is not routine in Singapore.


  • All pre-school children should be immunised against measles. Combined Measles/Mumps/Rubella (MMR) vaccine is given to all children between 12 and 15 months of age as part of the childhood immunisation programme in Singapore (see Appendix 2). Proof of vaccination is required for admissions to crèches, kindergartens and primary schools.
  • The second dose of MMR vaccine is now given to all primary I school entrants at around 6 years of age. Infected children should stay away from school for one week after onset of rash. All unimmunised children at the nursery or kindergarten where the infection occurred should be immunised as soon as possible.
    (See section on post-exposure prophylaxis for management of measles exposure in Appendix 1.)
  • All childhood vaccinations should be notified to the National Immunisation Registry, Health Promotion Board, and post-vaccination adverse reactions to the Pharmacovigilance Branch, Health Sciences Authority.










References

  1. Ong G, Heng BH, Ong A et al. A 24-year review on the epidemiology and control of measles in Singapore, 1981-2004. Southeast Asian J Trop Med Public Health 2006;37:96-101
  2. Perry RT, Halsey NA. The clinical significance of measles: a review. J Infect Dis 2004; 189:4-16
  3. Duke T, Mgone CS. Measles: not just another viral exanthem. Lancet 2004; 361:763-73
  4. Huiming Y, Chaomin W, Meng M. Vitamin A for treating measles in children. Cochrane Database Syst Rev 2005; 4:CD001479.





Last Updated on